Amato L, Minozzi S, Pani P P, Davoli M
ASL RM/E, Deparment of Epidemiology, Via di Santa Costanza 53, Rome, Lazio, Italy, 00198.
Cochrane Database Syst Rev. 2007 Jul 18(3):CD006306. doi: 10.1002/14651858.CD006306.pub2.
Cocaine dependence is a public health problem characterized by recidivism and a host of medical and psychosocial complications. Cocaine dependence remains a disorder for which no pharmacological treatment of proven efficacy exists, although considerable advances in the neurobiology of this addiction could guide future medication development
To evaluate the efficacy and the acceptability of antipsychotic medications for cocaine dependence
We searched the following sources: MEDLINE (1966 to October 2006), EMBASE (1980 to October 2006), CINAHL (1982 to October 2006), Cochrane Drug and Alcohol Group Specialised Register (October 2006). We also searched the reference lists of trials, the main electronic sources of ongoing trials (National Research Register, meta-Register of Controlled Trials; Clinical Trials.gov) and conference proceedings likely to contain trials relevant to the review. All searches included also non-English language literature.
All randomised controlled trials and controlled clinical trials with focus on the use of any antipsychotic medication for cocaine dependence
Two authors independently evaluated the papers, extracted data, rated methodological quality
Seven small studies were included (293 participants): the antipsychotic drugs studied were risperidone, olanzapine and haloperidol. No significant differences were found for any of the efficacy measures comparing any antipsychotic with placebo. Risperidone was found to be superior to placebo in diminishing the number of dropouts, four studies, 178 participants, Relative Risk (RR) 0.77 (95% CI 0.77 to 0.98). Most of the included studies did not report useful results on important outcomes such as side effects, use of cocaine during treatment and craving. The results on olanzapine and haloperidol come from studies too small to give conclusive results.
AUTHORS' CONCLUSIONS: Although caution is needed when assessing results from a limited number of small clinical trials there is no current evidence, at the present , supporting the clinical use of antipsychotic medications in the treatment of cocaine dependence. Furthermore, most of the included studies did not report useful results on important outcomes such as side effects, use of cocaine during the treatment and craving. Aiming to answer the urgent demand of clinicians, patients, families, and the community as a whole for an adequate treatment for cocaine dependence, larger randomised investigations should be designed investigating relevant outcomes and reporting data to allow comparison of results between studies. Moreover some efforts should be done also to investigate the efficacy of other type medications, like anticonvulsant, currently used in clinical practice.
可卡因成瘾是一个公共卫生问题,其特点是复发以及一系列医学和心理社会并发症。尽管在这种成瘾的神经生物学方面取得了相当大的进展,可指导未来药物开发,但可卡因成瘾仍然是一种尚无经证实有效的药物治疗方法的疾病。
评估抗精神病药物治疗可卡因成瘾的疗效和可接受性。
我们检索了以下来源:医学文献数据库(MEDLINE,1966年至2006年10月)、荷兰医学文摘数据库(EMBASE,1980年至2006年10月)、护理学与健康领域数据库(CINAHL,1982年至2006年10月)、Cochrane药物与酒精研究组专业注册库(2006年10月)。我们还检索了试验的参考文献列表、正在进行的试验的主要电子来源(国家研究注册库、对照试验元注册库;临床试验.gov)以及可能包含与该综述相关试验的会议论文集。所有检索还包括非英语语言文献。
所有聚焦于使用任何抗精神病药物治疗可卡因成瘾的随机对照试验和对照临床试验。
两位作者独立评估论文、提取数据、评定方法学质量。
纳入了7项小型研究(293名参与者);所研究的抗精神病药物为利培酮、奥氮平和氟哌啶醇。将任何一种抗精神病药物与安慰剂相比,在任何疗效指标上均未发现显著差异。在减少退出人数方面,发现利培酮优于安慰剂,4项研究,178名参与者,相对危险度(RR)0.77(95%可信区间0.77至0.98)。大多数纳入研究未报告关于重要结局的有用结果,如副作用、治疗期间可卡因的使用情况和渴求感。关于奥氮平和氟哌啶醇的结果来自规模过小而无法得出确定性结果的研究。
尽管在评估有限数量的小型临床试验结果时需要谨慎,但目前尚无证据支持在治疗可卡因成瘾时临床使用抗精神病药物。此外,大多数纳入研究未报告关于重要结局的有用结果,如副作用、治疗期间可卡因的使用情况和渴求感。为满足临床医生、患者、家庭以及整个社区对可卡因成瘾适当治疗的迫切需求,应设计更大规模的随机研究,调查相关结局并报告数据,以便能够比较不同研究的结果。此外,还应做出一些努力来研究目前临床实践中使用的其他类型药物(如抗惊厥药)的疗效。